Evidence map›Paper›PMID 39993187›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Chemical genetic interactions elucidate pathways controlling tuberculosis antibiotic efficacy during infection.

Peter O Oluoch, Eun-Ik Koh, Megan K Proulx, Charlotte J Reames, Kadamba G Papavinasasundaram, Kenan C Murphy, Matthew D Zimmerman, Véronique Dartois, Christopher M Sassetti

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Predicting fitness inFrontiers in tuberculosis · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Peter O OluochDepartment of Microbiology, University of Massachusetts Medical School, Worcester, MA 01655.ORCID 0000-0001-7451-4993
Eun-Ik KohDepartment of Microbiology, University of Massachusetts Medical School, Worcester, MA 01655.ORCID 0000-0003-2220-5229
Megan K ProulxDepartment of Microbiology, University of Massachusetts Medical School, Worcester, MA 01655.ORCID 0000-0002-9524-8302
Charlotte J ReamesDepartment of Microbiology, University of Massachusetts Medical School, Worcester, MA 01655.ORCID 0000-0001-5579-5881
Kadamba G PapavinasasundaramDepartment of Microbiology, University of Massachusetts Medical School, Worcester, MA 01655.ORCID 0000-0001-7837-1344
Kenan C MurphyDepartment of Microbiology, University of Massachusetts Medical School, Worcester, MA 01655.ORCID 0000-0002-3677-2876
Matthew D ZimmermanCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.
Véronique DartoisCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.ORCID 0000-0001-9470-5009
Christopher M SassettiDepartment of Microbiology, University of Massachusetts Medical School, Worcester, MA 01655.ORCID 0000-0001-6178-4329

Funding

Vulnerabilities in Mycobacterial Cell-Wall BiogenesisP01AI095208 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI SASSETTI, CHRISTOPHER M · 2012 to 2022
$19.8M
Systems Biology CoreU19AI162598 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI ALLAND, DAVID, ELLNER, JERROLD J. · 2021 to 2025
$13.9M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI095208HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI162598NIAID NIH HHS P01 AI095208NIAID NIH HHS U19 AI162598
6 · The paper itself

Abstract

Successful tuberculosis therapy requires treatment with an unwieldy multidrug combination for several months. Thus, there is a growing need to identify novel genetic vulnerabilities that can be leveraged to develop new, more effective antitubercular drugs. Consequently, recent efforts to optimize tuberculosis (TB) therapy have exploited

Indexed as

Antitubercular AgentsMycobacterium tuberculosisTuberculosisAnimalsDisease Models, AnimalFemaleMiceMice, Inbred C57BLPyrazinamideAntitubercular AgentsPyrazinamidechemical–genetic interactionsin vivoMycobacterium tuberculosispyrazinamidesynergistic interactions

Identifiers

PMID39993187
PMCPMC11892619

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.